Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene therapy for CNS degeneration

A kind of therapy, transgenic technology, applied in the field of gene therapy of CNS degeneration, can solve few problems such as gene therapy of central nervous system degeneration

Pending Publication Date: 2021-02-12
ROCKET PHARMA LTD
View PDF17 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite extensive attempts, there are few reports of successful gene therapy for CNS degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene therapy for CNS degeneration
  • Gene therapy for CNS degeneration
  • Gene therapy for CNS degeneration

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0379] Evaluation of Parkin transgenic variants

[0380] A series of plasmid vectors was generated to evaluate the expression of Parkin transgenic variants. expression cassette ( figure 1 ) contains in 5' to 3' order the CMV immediate early (IE) enhancer / promoter and 5'UTR, Parkin transgene 2A linked to enhanced green fluorescent protein (eGFP), 3'UTR and rabbit globin polyadenylation Acidifying sequence (polyA). The wild-type sequence (WT) or one of four codon-optimized variants (CO1 to CO4) of human PRKN were tested against the Parkin transgene. The sequences of wild-type and codon-optimized Parkin transgenes are provided in SEQ ID NO:27, 35, 36, 37 and 38.

[0381] One consideration in the design of codon-optimized CO1 to CO4 is the number of CpG sites. A CpG island is a region of DNA in which cytosine nucleotides are followed by guanine nucleotides in a linear sequence of bases along its 5'→3' direction. CpG islands (which are generally defined as polynucleotide sequ...

example 2

[0389] Selection of CO4 Parkin Transgene Expression Cassette

[0390] To assess other regulatory elements, various AAV expression cassettes were constructed as transfer plasmids for use in the helper-free AAV packaging system. AAV expression cassette ( Figure 7 ) contains in 5' to 3' order the 5'ITR of AAV2, the CMV enhancer (Enh) or no enhancer, a promoter selected from Table 5, a 5' untranslated region (UTR) selected from Table 6, a Parkin transgene Variant CO4 (SEQ ID NO:38), 3' untranslated region selected from Table 7, polyadenylation sequence (polyA) selected from Table 8, and 3'ITR of AAV2. A diagram of the box and various components is provided at Figure 8 middle. For detection of transgene expression in in vitro assays, the polynucleotide sequence (SEQ ID NO:80) encoding the N-terminal FLAG / HA-tag (SEQ ID NO:81) is in each of the sequences listed in Table 10 Inserted after the start codon on the Parkin transgene.

[0391] SH-SY5Y cells were cultured on 24-well ...

example 3

[0400] In vivo and clinical testing of Parkin AAV gene therapy

[0401] AAV vectors were generated by packaging the AAV vector genomes from constructs 1 to 20 in Example 2, specifically constructs 1, 7, 11 and 15 from Table 11. Testing is performed in rats, and one or more constructs are selected for testing in non-human primates (NHPs). Dose finding studies are performed and the starting dose for clinical trials is determined by measuring protein expression and observed toxicity.

[0402] The clinical trial was conducted in subjects identified as having a recessive mutation in the PRKN gene (also known as PRK2). Protein expression and observed toxicity were used to determine optimal doses. Efficacy was assessed using a modification of the Unified Parkinson's Disease Rating Scale (UPDRS).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates generally to compositions and methods for treating, preventing, inhibiting, or delaying central nervous system degeneration. The disclosure relates to a recombinant genetherapy vector comprising a PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA gene, or functional fragment or variant thereof. The disclosure also relates to CRISPR / Cas-based gene editing systems for treating, preventing, inhibiting, or delaying central nervous system degeneration.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 664,006, filed April 27, 2018, the disclosure of which is hereby incorporated by reference in its entirety for all purposes. [0003] Incorporation of Sequence Listings [0004] The Sequence Listing related to this application is provided in text format in lieu of a paper copy and is incorporated by reference into this specification. The name of the text file containing the sequence listing is ROPA_009_01WO_ST25.txt. The text file is 254KB, created on April 29, 2019 and submitted electronically via EFS-Web. technical field [0005] The present disclosure generally relates to gene therapy and / or gene editing for the treatment of disorders associated with central nervous system degeneration, such as Parkinson's Disease. In particular, the present disclosure provides compositions and methods for gene therapy or gene repair in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/86C12N9/22C12N15/85C12N15/63
CPCC12N15/63C12N9/22C12N15/86C12N2750/14143C07K14/47A61K48/005C12N2800/22C12N9/93C12N9/12C12N9/0012C07K14/82C12N9/24C12N15/85A61P25/16C12N15/113C12N2310/20A61K9/0085A61K48/00C12N9/104C12N15/11C12N15/907C12N2800/80C12Y203/02
Inventor A·喀拉瓦拉P·巴蒂普鲁R·普拉巴卡R·王P·普拉苏旺N·雅拉曼奇
Owner ROCKET PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com